依达拉奉右莰醇对急性脑梗死疗效的性别差异研究  

Gender difference in the treatment of acute ischemic stroke with edaravone dextrocamphorol injection solution

作　　者：叶茹 傅永旺 姚远 YE Ru;FU Yongwang;YAO Yuan(Department of Neurology,Inner Mongolia People’s Hospital,Hohhot 010017,China;Inner Mongolia Medical University,Hohhot 010017,China;School of Life Sciences,Inner Mongolia University,Hohhot 010070,Inner Mongolia,China;Inner Mongolia Academy of Medical Sciences,Hohhot 010017,Inner Mongolia,China)

机构地区：[1]内蒙古自治区人民医院神经内科,内蒙古呼和浩特010017 [2]内蒙古医科大学研究生学院,内蒙古呼和浩特010017 [3]内蒙古大学生命科学院,内蒙古呼和浩特010070 [4]内蒙古医学科学院,内蒙古呼和浩特010017

出　　处：《中国现代医生》2025年第8期59-61,共3页China Modern Doctor

基　　金：内蒙古自治区卫生健康科技计划项目(202202028);内蒙古自治区科技计划项目(2022YFSH0133)。

摘　　要：目的从性别的角度探讨依达拉奉右莰醇对急性脑梗死(acute ischemic stroke,AIS)患者治疗效果的差异。方法选取2023年2月至2024年1月在内蒙古自治区人民医院神经内科住院治疗的AIS患者180例为研究对象。根据患者性别,分为女性组(n=120)和男性组(n=60)。记录并比较两组患者的临床资料。评估指标包括治疗前、后14d美国国立卫生研究院卒中量表评分及治疗后3个月的神经功能恢复状况的量表评分,并观察两组的不良药物反应及不良事件。结果经过14d的依达拉奉右莰醇治疗,女性患者的总有效率明显高于男性患者,差异有统计学意义(P=0.034);出院后3个月的随访结果显示,两组患者远期预后比较,差异无统计学意义,且两组患者均未发生药物不良反应或与药物相关的不良预后。结论女性AIS患者在接受依达拉奉右莰醇治疗后,其近期临床预后较男性患者可能更为理想,而远期预后无性别差异。Objective To explore the gender difference of clinical efficacy of edaravone dextrocamphorol injection solution in the treatment of acute ischemic stroke(AIS)patients.Methods A total of 180 AIS patients treated in Inner Mongolia People’s Hospital from February 2023 to January 2024 were selected and divided into female group(n=120)and male group(n=60)by gender.Clinical data of two groups were recorded,and compared with differences.Evaluation indicators included the National Institutes of Health stroke scale score before and 14d after treatment.and the neurological recovery scale score at 3 months after treatment.A adverse drug reactions and adverse events were observed in both groups.Results After 14 days of treatment with edaravone dextrocamphorol injection solution,total effective rate of female patients was better than that of male patients,difference was statistically significant(P=0.034).At 3 months follow-up after discharge,there was no significant difference in long-term prognosis between two groups,and no adverse drug reactions or drug-related adverse prognosis occurred in two groups.Conclusion Short-term clinical prognosis of female AIS patients receiving edaravone dextrocamphorol injection solution concentrated solution is better than that of male patients.There was no gender difference in long-term prognosis.

关 键 词：急性脑梗死 性别差异 依达拉奉右莰醇 

分 类 号：R543.6[医药卫生—心血管疾病]